| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 1,103,315 | 1,346,844 | ||
| Prepaid expenses and other | 611,786 | 709,340 | ||
| Total current assets | 1,715,101 | 2,056,184 | ||
| Research and development supplies | 1,847,412 | 1,771,340 | ||
| Total other assets | 1,847,412 | 1,771,340 | ||
| Total assets | 3,562,513 | 3,827,524 | ||
| Accounts payables | 1,619,446 | 930,812 | ||
| Other current liabilities | 932,260 | 1,505,517 | ||
| Total current liabilities | 2,551,706 | 2,436,329 | ||
| Derivative liabilities | 243,000 | - | ||
| Total liabilities | 2,794,706 | - | ||
| Common stock 0.001 par value 200,000,000 shares authorized 1,004,247 and 217,234 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 1,004 | 33,145 | ||
| Additional paid-in capital | 168,004,988 | 164,796,996 | ||
| Accumulated deficit | -167,238,185 | -163,438,946 | ||
| Total stockholders equity | 767,807 | 1,391,195 | ||
| Total liabilities and stockholders equity | 3,562,513 | 3,827,524 | ||
Genprex, Inc. (GNPX)
Genprex, Inc. (GNPX)